Cite
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.
MLA
Kwak, Larry W., et al. “Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.” Clinical Lymphoma, Myeloma & Leukemia, vol. 22, no. 2, Feb. 2022, pp. 89–97. EBSCOhost, https://doi.org/10.1016/j.clml.2021.08.005.
APA
Kwak, L. W., Sancho, J.-M., Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Menne, T., Mariz, J., Ilyin, N., Jurczak, W., Martinez, A. L., Samoilova, O., Zhavrid, E., Ruiz, E. Y., Trneny, M., Popplewell, L., Ogura, M., Won-Seog Kim, & Sang Joon Lee. (2022). Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Clinical Lymphoma, Myeloma & Leukemia, 22(2), 89–97. https://doi.org/10.1016/j.clml.2021.08.005
Chicago
Kwak, Larry W., Juan-Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, et al. 2022. “Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.” Clinical Lymphoma, Myeloma & Leukemia 22 (2): 89–97. doi:10.1016/j.clml.2021.08.005.